Mechanism Activity and Spesific Chemical Compound of Purslane (Portulaca oleracea L.) in Managing Obesity: A Systematic Literature Review

Rizqi Nur Azizah; Fadlina Chany Saputri; Meidi Utami Puteri; Aktsar Roskiana Ahmad

doi:10.24036/eksakta/vol27-iss05/734

EKSAKTA: Berkala Ilmiah Bidang MIPA

Open Access

**Mechanism Activity and Spesific Chemical Compound of Purslane (Portulaca oleracea L.) in Managing Obesity: A Systematic Literature Review**

Rizqi Nur Azizah ¹

, Fadlina Chany Saputri ¹

, Meidi Utami Puteri ¹

, Aktsar Roskiana Ahmad ²

¹ Department of Pharmacology-Toxicology, Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia

² Laboratory of Pharmacognosy and Phytochemistry, Faculty of Pharmacy, ¬Universitas Muslim Indonesia, Makassar, Indonesia

Published 2026-10-29

Vol. 27 No. 05 (2026) PAGES 1002-1011

DOI 10.24036/eksakta/vol27-iss05/734

Views / Downloads 0 0

Download PDF

Abstract

Obesity is global health problem characterized by an increase in body fat, leading to adverse metabolic, biomechanical, and psychosocial health consequences. Herbal supplementation have become increasingly popular due with fewer adverse effects and lower cost Previous study showed that Portulaca oleracea L. (PO) are one of the plants that can treating obesity. This revew demonstrates that PO exhibits potential as an alternative therapeutic agent in the management of obesity through multiple pharmacological mechanisms, including reduced weight gain & body fat, improved insulin sensitivity, reduced LDL-C, triglycerides, Improved weight, BMI, liver function with multiple mechanisms that can help manage obesity, primarily through its antioxidant, anti-inflammatory, and lipid & glucose methabolism regulation. These effects are associated with the synergistic action of its bioactive constituens, including homoisoflavonoids, oleracein E and oleracein L, omega-3 Fatty Acids (ALA), quercetin, rutin, and polyphenolic compound. The dose effevtive in animal studies is between 5%-10% extract PO for 12 weeks and 500-700 mg for 4-8 weeks in clinical trial. This eview articles suggest a need for further, advanced-phase clinical trials in humans to establish an optimal and safe dosage for long-term use.

References

1

[1] Ruddock, J.S., Goswami, G.(2023).Obesity. Handbook of Outpatient Medicine: Second Edition,

2

[2] Aydin, M.R.(2022).Obesity. Chronic Disease Follow-Ups for Adults in Primary Care,

3

[3] Müller, T. D., & Blüher, M. (2023). Obesity treatment: will pharmacotherapies replace metabolic surgery in the future?. Innere Medizin (Heidelberg, Germany), 1.

4

[4] Faucher, P., & Poitou, C. (2016). Physiopathology, causes and complications of obesity. Soins; la Revue de Reference Infirmiere, 61(811), 20-25.

5

[5] Milewicz, A., & Kubicka, E. (2015). Metabolic Healthy Obesity and Metabolic Obesity with Normal Weight and CVD Risk in Women. In Frontiers in Gynecological Endocrinology: Volume 3: Ovarian Function and Reproduction-From Needs to Possibilities (pp. 111-116). Cham: Springer International Publishing.

6

[6] Mehrzad, R. (2020). Definition and introduction to epidemiology of obesity. In Obesity (pp. 1-6). Elsevier.

7

[7] Hauner, H. (2016). Obesity: Influence on Diabetes and Management. In Type 2 Diabetes (pp. 409-418). CRC Press.

8

[8] Cheskin, L. J., Frutchey, R. A., Bunyard, L., & Glascoe, S. (2015). Obesity management. In Encyclopedia of Food and Health (pp. 126-131). Elsevier Inc..

9

[9] Kiwanuka, E. (2020). The health impact of obesity. In Obesity (pp. 73-83). Elsevier.

10

[10] Mazaheri, T., Ansari, S., Nallagonda, M., Kollmann, L., Nickel, F., Seyfried, F., & Miras, A. D. (2023). Pharmacotherapy of obesity-Competition to bariatric surgery or a meaningful supplement?. Chirurgie (Heidelberg, Germany), 94(6), 497-505.

11

[11] Kiwanuka, E. (2020). The role of physical activity in the obesity epidemic. In Obesity (pp. 109-115). Elsevier.

12

[12] Mazzarone, F., Chamma, R. S., & Manente, M. M. (2024). Thoracobrachioplasty. In Body Contouring: Current Concepts and Best Practices (pp. 803-808). Cham: Springer International Publishing.

13

[13] WHO. (2024). Obesity. Link : https://www.who.int/health-topics/obesity.

14

[14] Zhou, Y. X., Xin, H. L., Rahman, K., Wang, S. J., Peng, C., & Zhang, H. (2015). Portulaca oleracea L.: a review of phytochemistry and pharmacological effects. BioMed research international, 2015(1), 925631.

15

[15] Syed, S., Fatima, N., & Kabeer, G. (2016). Portulaca oleracea L.: a mini review on phytochemistry and pharmacology. International journal of Biology and Biotechnology, 13(4), 637-641.

16

[16] Jung, J. H., Hwang, S. B., Park, H. J., Jin, G. R., & Lee, B. H. (2021). Antiobesity and antidiabetic effects of Portulaca oleracea powder intake in high‐fat diet‐induced obese C57BL/6 mice. Evidence‐Based Complementary and Alternative Medicine, 2021(1), 5587848.

17

[17] Azizah, R. N. (2019). Antirheumatoid Artritis Effect of Purslane Herb Extract (portulaca oleracea l.) to Rat (rattus norvegicus) Induced by Complete Freuds Adjuvant. Journal of Global Pharma Technology, 11(4), 314-319.

18

[18] Asmaliani, I., Putra, B., Emelda, A., & Azizah, R. N. (2024). Histopathological Profile of Rats (Rattus norvegicus) with Collagen-Type II Rheumatoid Arthritis and treated with Purslane Tea (Portulaca oleracea Linn.). Tropical Journal of Natural Product Research, 8(6), 7526.

19

[19] Nemzer, B., Al-Taher, F., & Abshiru, N. (2020). Phytochemical composition and nutritional value of different plant parts in two cultivated and wild purslane (Portulaca oleracea L.) genotypes. Food chemistry, 320, 126621.

20

[20] Vajdi, M., Hassanizadeh, S., Shojaei-Zarghani, S., Bagherniya, M., & Askari, G. (2023). The Effects of Purslane Consumption on Obesity Indices: A GRADE‐Assessed Systematic Review and Meta‐Analysis of Randomized Controlled Trials. Journal of Food Biochemistry, 2023(1), 6655305.

21

[21] Azizah, R. N., Emelda, A., Asmaliani, I., Ahmad, I., & Fawwaz, M. (2022). Total phenolic, flavonoids, and carotenoids content and anti-obesity activity of purslane herb (Portulaca oleracea L.) ethanol extract. Pharmacogn J, 14(1), 8-13.

22

[22] Putra, R. P., Aisyah, S. I., & Nurcholis, W. (2023). Benefits of total phenolic and flavonoid content of Portulaca oleracea as antioxidant and antidiabetic: a review. Trop J Nat Prod Res, 7(2), 2293-2304.

23

[23] Zhang, H., Chen, G., Yang, J., Yang, C., & Guo, M. (2022). Screening and characterisation of potential antioxidant, hypoglycemic and hypolipidemic components revealed in Portulaca oleracea via multi‐target affinity ultrafiltration LC–MS and molecular docking. Phytochemical Analysis, 33(2), 272-285.

24

[24] Kim, K. H., Park, E. J., Jang, H. J., Lee, S. J., Park, C. S., Yun, B. S., ... & Rho, M. C. (2019). 1-carbomethoxy-β-Carboline, derived from Portulaca oleracea L., ameliorates LPS-mediated inflammatory response associated with MAPK signaling and nuclear translocation of NF-κB. Molecules, 24(22), 4042.

25

[25] Shafi, S., & Tabassum, N. (2016). Evaluation of antidiabetic and hypolipidemic activities of ethanolic extract of Portulaca oleracea (whole plant) in alloxan induced diabetic rats. Int. J Pharm Sci Rev Res, 38, 64-69.

26

[26] Chen, W. C., Wang, S. W., Li, C. W., Lin, H. R., Yang, C. S., Chu, Y. C., ... & Chen, J. J. (2022). Comparison of various solvent extracts and major bioactive components from Portulaca oleracea for antioxidant, anti-tyrosinase, and anti-α-glucosidase activities. Antioxidants, 11(2), 398.

27

[27] Heras, L. E. G., Mir, V. G., Rubio, O. C., Jaramillo, C. G. J., & Japón, G. E. R. (2017). Composición química y actividad antiinflamatoria de extracto de partes aéreas de Portulaca oleracea (verdolaga). Revista Cubana de Farmacia, 51(1).

28

[28] Iranshahy, M., Javadi, B., Iranshahi, M., Jahanbakhsh, S. P., Mahyari, S., Hassani, F. V., & Karimi, G. (2017). A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L. Journal of ethnopharmacology, 205, 158-172.

29

[29] Rahimi, V. B., Ajam, F., Rakhshandeh, H., & Askari, V. R. (2019). A pharmacological review on Portulaca oleracea L.: focusing on anti-inflammatory, anti-oxidant, immuno-modulatory and antitumor activities. Journal of pharmacopuncture, 22(1), 7.

30

[30] El-Sayed, M. I. K. (2011). Effects of Portulaca oleracea L. seeds in treatment of type-2 diabetes mellitus patients as adjunctive and alternative therapy. Journal of ethnopharmacology, 137(1), 643-651.

31

[31] Chan, K., Islam, M. W., Kamil, M. A., Radhakrishnan, R., Zakaria, M. N. M., Habibullah, M., & Attas, A. (2000). The analgesic and anti-inflammatory effects of Portulaca oleracea L. subsp. sativa (Haw.) Celak. Journal of ethnopharmacology, 73(3), 445-451.

32

[32] Karimi, G., Hosseinzadeh, H., & Ettehad, N. (2004). Evaluation of the gastric antiulcerogenic effects of Portulaca oleracea L. extracts in mice. Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 18(6), 484-487.

33

[33] Iranshahy, M., Javadi, B., Iranshahi, M., Jahanbakhsh, S. P., Mahyari, S., Hassani, F. V., & Karimi, G. (2017). A review of traditional uses, phytochemistry and pharmacology of Portulaca oleracea L. Journal of ethnopharmacology, 205, 158-172.

34

[34] Uddin, M. K., Juraimi, A. S., Hossain, M. S., Nahar, M. A. U., Ali, M. E., & Rahman, M. M. (2014). Purslane weed (Portulaca oleracea): A prospective plant source of nutrition, omega‐3 fatty acid, and antioxidant attributes. The Scientific World Journal, 2014(1), 951019.

35

[35] Sabzghabaee, A. M., Kelishadi, R., Jelokhanian, H., Asgary, S., Ghannadi, A., & Badri, S. (2014). Clinical effects of Portulaca oleracea seeds on dyslipidemia in obese adolescents: a triple-blinded randomized controlled trial. Medical Archives, 68(3), 195.

36

[36] Milkarizi, N., Barghchi, H., Belyani, S., Bahari, H., Rajabzade, F., Ostad, A. N., ... & Askari, V. R. (2024). Effects of Portulaca oleracea (purslane) on liver function tests, metabolic profile, oxidative stress and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinical trial. Frontiers in Nutrition, 11, 1371137.

37

[37] Yehia, R., Lone, I. M., Yehia, I., & Iraqi, F. A. (2023). Studying the Pharmagenomic effect of Portulaca oleracea extract on anti-diabetic therapy using the Collaborative Cross mice. Phytomedicine Plus, 3(1), 100394.

38

[38] Wang H., Li G., Yang J., Chen C., Zhang N., Sun J., Qin N., Liu X. (2023). Lipid-Lowering Effect of Portulaca oleracea L. Polyunsaturated Fatty Acids on Hyperlipidemia Rats. Journal of the Chinese Cereals and Oils Association, 38 (3), pp. 144 – 150

39

[39] Aini, N. S., Ansori, A. N. M., Kharisma, V. D., Syadzha, M. F., Widyananda, M. H., Murtadlo, A. A. A., ... & Zainul, R. (2022). Potential roles of purslane (Portulaca oleracea L.) as antimetabolic syndrome: A review. Pharmacognosy Journal, 14(3), 710-714.

40

[40] Lee, J. H., Park, J. E., & Han, J. S. (2020). Portulaca oleracea L. extract reduces hyperglycemia via PI3k/Akt and AMPK pathways in the skeletal muscles of C57BL/Ksj-db/db mice. Journal of Ethnopharmacology, 260, 112973.

41

[41] Karamalakova, Y., Petkova-Parlapanska, K., Hinkov, I., Vetskov, N., Georgieva, E., & Nikolova, G. (2024). The effect of radiation preservation on macromolecule content, antimicrobial activity and radical-scavenging potential of Portulaca oleracea L. leaves extract. Journal of Chemical Technology and Metallurgy, 59(2), 243-249.

42

[42] Oyabambi, A. O., Aindero, B. B., Awolola, A. M., Adebayo, A. Y., Iluromi, I. B., & Olorunniyi, K. S. (2024). Portulaca oleracea (purslane) aqueous extract reduced the adverse metabolic outcomes and favored liraglutide activities in streptozotocin-induced cardiometabolic disorders of male Wistar rats. Endocrine and Metabolic Science, 16, 100191.

43

[43] Tafti, M. A., Moein, M., Babajafari, S., Haem, E., & Zarshenas, M. M. (2024). Efficacy of herbal supplementation of purslane freeze-dried juice for weight loss: An 8-week randomized, double-blind, placebo-controlled clinical trial. Current Traditional Medicine, 10(1), 81-90.

44

[44] Roozi, H., Bojar, M. N., Eidi, V., & Ali, K. N. R. (2019). Effects of oleracein E and oleracein L from Portulaca oleracea on cell survival, antioxidant and antidiabetic efficacy on beta-TC-6 pancreatic cell line. Indian Journal of Pharmaceutical Sciences, 81(4), 681-689.

45

[45] Alfwuaires, M. A., Algefare, A. I., Afkar, E., Salam, S. A., Abd El-Moaty, H. I., & Badr, G. M. (2021). Immunomodulatory assessment of Portulaca oleracea L. extract in a mouse model of colitis. Biomedicine & Pharmacotherapy, 143, 112148.

46

[46] Shao, G., Liu, Y., Lu, L., Wang, L., Ji, G., & Xu, H. (2024). Therapeutic potential of traditional Chinese medicine in the prevention and treatment of digestive inflammatory cancer transformation: Portulaca oleracea L. as a promising drug. Journal of Ethnopharmacology, 327, 117999.

47

[47] Shanker, N., & Debnath, S. (2015). Impact of dehydration of purslane on retention of bioactive molecules and antioxidant activity. Journal of food science and technology, 52(10), 6631-6638.